Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
625 results about "D-GLUCURONIC ACID" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The β-D-methyl glycoside of glucuronic acid in the low energy 4C1 conformation of D-glucose. Glucuronic acid is a sugar acid derived from glucose, with its sixth carbon atom oxidized to a carboxylic acid. In living beings, this primary oxidation occurs with UDP-α-D-glucose (UDPG), not with the free sugar.
Analyte injection system
InactiveUS20050133370A1Increase in sizeShort amount of timeSludge treatmentVolume/mass flow measurementGlutaric acidAntibody conjugate
This invention provides methods and devices for spatially separating at least first and second components in a sample which in one exemplary embodiment comprises introducing the first and second components into a first microfluidic channel of a microfluidic device in a carrier fluid comprising a spacer electrolyte solution and stacking the first and second components by isotachophoresis between a leading electrolyte solution and a trailing electrolyte solution, wherein the spacer electrolyte solution comprises ions which have an intermediate mobility in an electric field between the mobility of the ions present in the leading and trailing electrolyte solutions and wherein the spacer electrolyte solution comprises at least one of the following spacer ions MOPS, MES, Nonanoic acid, D-Glucuronic acid, Acetylsalicyclic acid, 4-Ethoxybenzoic acid, Glutaric acid, 3-Phenylpropionic acid, Phenoxyacetic acid, Cysteine, hippuric acid, p-hydroxyphenylacetic acid, isopropylmalonic acid, itaconic acid, citraconic acid, 3,5-dimethylbenzoic acid, 2,3-dimethylbenzoic acid, p-hydroxycinnamic acid, and 5-br-2,4-dihydroxybenzoic acid, and wherein the first component comprises a DNA-antibody conjugate and the second component comprises a complex of the DNA-antibody conjugate and an analyte.
Owner:WAKO PURE CHEMICAL INDUSTRIES +1
(3) and (6) substitued estrogenic compounds
Novel estrogenic compounds of Formula I are provided. wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an α or a β orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
Owner:DURAMED PHARMA
(3) and (6) substituted estrogenic compounds
Novel estrogenic compounds of Formula I are provided.wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1 does not exist; R2 is lower alkyl; R3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R4 through R13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower allyl, lower alkoxy, halogen, and carbonyl groups and R14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R1 is hydroxy, the hydroxy or ester substituent may have either an α or a β orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
Owner:DURAMED PHARMA
Modification of xylan
InactiveUS20130233501A1Low water solubilityReduce solubilityNon-fibrous pulp additionSpecial paperSolubilityCellulose
The invention provides a method of modifying soluble xylan which contains glucuronic acid and / or arabinose side chains so that it can be adsorbed onto other substrates. The method includes the steps of enzymatically modifying the xylan by selectively removing glucuronic acid and / or arabinose side chains from the xylan with α-D-glucuronidase and / or α-L-arabinofuranosidase, and allowing the modified xylan to adsorb onto the substrate. The substrate may be a cellulosic substrate like pulp or paper or a non-cellulosic substrate. The enzymes are able to remove a sufficient number of the xylan side chains so as to decrease water solubility of the xylan, induce xylan precipitation and allow adsorption of the xylan onto other substrates. A pulping process which incorporates modification of xylan and adsorption onto cellulosic material is also provided, as are products which contain the modified xylan.
Owner:STELLENBOSCH UNIVERSITY
Oligomerization pineapple ginseng glycosaminoglycan and preparation method thereof
ActiveCN101724086AGood anticoagulant and antithrombotic activityOrganic active ingredientsBlood disorderMonosaccharide compositionEnzyme inhibitor
Owner:SHENZHEN NEPTUNUS PHARM CO LTD
Resveratrol and bioflavonoid nutritional composition for delaying senility
InactiveCN101632655AExtended stayExtension of timeHydroxy compound active ingredientsMetabolism disorderDiseaseSulfate
The invention relates to a resveratrol and bioflavonoid nutritional composition for delaying senility or used for treating and preventing diseases relevant to aging. The invention adopts the combination of resveratrol and bioflavonoid and prepares oral liquid, capsules, tablets, granules and powder. The invention overcomes the defect that the absorptivity of antitype resveratrol in the prior art is very high, but the bioavailability is very low; A composition of the resveratrol and quercetin can prolong the detention time of the resveratrol in blood and enhance the acting time of the resveratrol, but only part of the resveratrol is not metabolized and acts together with the quercetin to enhance the function of delaying senility; and the rest part of the resveratrol after being converted into the sulfate or glucuronic acid salt of the resveratrol by metabolism does not generate a synergistic action with the quercetin again, and the effect of the resveratrol for delaying senility is lowered. The invention greatly prolongs the detention time of the resveratrol in a human body, exerts the function of the resveratrol for resisting senility, solves the problem that the resveratrol is metabolized, and is innoxious.
Owner:南京大渊美容保健有限公司
Preparation method and applications of forsythoside glucuronic acid derivative
ActiveCN106188176AAvoid inactivationGuaranteed reaction selectivitySugar derivativesAntiviralsStereochemistryD-GLUCURONIC ACID
The present invention provides a preparation method, antivirus applications and the like of a forsythoside glucuronic acid derivative represented by the following formula, wherein R is H, Me, Na<+>, K<+>, and the like.
Owner:富力
Peach gum polysaccharide, its extractive, preparation method and application thereof
ActiveCN102372789AMeet the use requirementsAvoid decompositionCosmetic preparationsToilet preparationsNatural stateSpecific rotation
The invention discloses a peach gum polysaccharide, comprising 70-98 wt% of neutral total sugar and no nucileic acid, protein, tannin, dextrin, starch and other impurities, wherein, the content of glucuronic acid in the neutral total sugar accounts for 5-30 % of the content of the peach gum polysaccharide, the average molecular weight of the peach gum polysaccharide is more than 3000 dalton, and an aqueous solution of the peach gum polysaccharide has a dynmaic viscosity of 0.5-4.0 pa. s, a pH value of 4.0-6.5, and a specific rotation defined in the description. The invention also provides an extractive of the peach gum polysaccharide, and a preparation method of the peach gum polysaccharide and the extractive, and an application as a stabilizing agent. The preparation method of the peach gum polysaccharide and the extractive can ensure that various physicochemical properties of the peach gum polysaccharide satisfy the requirements of use in food, medicines, cosmetics, and light industry field, keeps natural state of the peach gum polysaccharide, has no effluence on the product properties of the peach gum polysaccharide, ensures the safety, stability, validity and controllability of the product, and has a wide commercial prospect and application future.
Owner:SHANGHAI HUIWEN BIO TECH
Process for producing water-soluble hyaluronic acid modification
ActiveUS20090148534A1Avoid unsafe practicesImprove securityPowder deliverySugar derivativesCross-linkSolvent
The present invention provides a water-soluble modified HA practically used as a drug carrier and a production method thereof. The present invention provides: a water-soluble modified hyaluronic acid, the residence time in blood of which is elongated to a practical level, which is produced by introducing a substituent into the carboxy group of the glucuronic acid of hyaluronic acid or a derivative thereof, via an amide bond, at a lower limit of an introduction rate of 5 mole % or more, using a BOP condensing agent in an aprotic polar solvent; and a production method thereof. Moreover, by cross-linking the modified hyaluronic acid, the present invention provides a hyaluronic acid gel capable of extremely long drug sustained-release even at the same cross-linking functional group introduction rate as that of the conventionally known gel.
Owner:CHUGAI PHARMA CO LTD
Fucosan sulphate, preparation method thereof, and application of fucosan sulphate in preparing anti-influenza virus medicine
The invention belongs to the field of marine medicines, and relates to a fucosan sulphate, a preparation method thereof and application of the fucosan sulphate in preparing an anti-influenza virus medicine. Polysaccharide with a main chain taking alpha-1,2-D-mannose and beta-1,4-D-glucuronic acid as repetitive units, and with a branched chain of alpha-1,3-L-fucosan sulphate is obtained by virtue of hot-water extraction, calcium chloride precipitation and DEAE-Cellulose chromatographic column purification. The fucosan sulphate prepared by the invention is high in inhibition effect on the influenza virus neuraminidase activities of A H1N1, H5N1 and H3N2, and obvious in protection effect on the dog kidney epithelial cells infected by A H1N1. The fucosan sulphate provided by the invention has the advantages of being rich in raw material source, simple in preparation process, easy to industrialize, high in product water solubility, high in stability, free from toxic and side effects, and the like, and has the prospect of being developed to the anti-influenza virus medicine.
Owner:威海人生药业有限公司
Fucosylated glycosaminoglycan derivative and preparation method thereof
InactiveCN102329397APotent anticoagulant activityOrganic active ingredientsBlood disorderOrganosulfateCarboxylic ester
The invention discloses a carboxylic ester of fucosylated glycosaminoglycan (CEFG) with anticoagulation activity, a pharmaceutically acceptable salt thereof, a preparation method of the CEFG and the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the CEFG or the salt thereof, and application of the pharmaceutical composition in preparation of anticoagulants. The monosaccharides for preparing the CEFG comprise D-glucuronic acid or D-glucuronate (D-GlcU), D-2-deoxy-2-acetyl galactosamine sulfate (D-GalNAcS) and L-fucose sulfate (L-FucS), wherein the molar ratio of D-GlcU to D-GalNAc to L-Fuc to -OSO3<-> is 1:(1+ / -0.3):(1+ / -0.3):(3.5+ / -0.5); the esterification degree of the D-GlcU is not lower than 20%; and the weight average molecular weight of the CEFG is 3000-20000 Da. The glycosylated chondroitin sulfate esterification derivative has strong anticoagulation activity, and can be applied in preparation of drugs for preventing and / or treating thrombotic diseases.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Long-chain chondroitin sugar chain and method for producing the same and method for promoting synthesis of chondroitin
ActiveUS20090263867A1Efficient productionEasy to produceBacteriaSugar derivativesFiltrationChondroitinase ABC
A method for producing a chondroitin sugar chain comprises at least the following step: a step of allowing “a glucuronic acid donor”, “an N-acetyl galactosamine donor”, “a sugar receptor” and “a bacterial cell enzyme which synthesizes chondroitin” to coexist in a reaction system in the presence of a surfactant. Here, the surfactant is preferably selected from n-nonyl-β-D-thiomaltopyranoside, sucrose monocaproate and sucrose monolaurate. The chondroitin sugar chain has all the following properties 1) to 3): 1) a weight average molecular weight: 50,000 or more when it is measured by gel filtration chromatography, 2) it is completely degraded to disaccharides with chondroitinase ABC, 3) when the sugar chain is decomposed with chondroitinase ABC and the decomposed products are subjected to a disaccharide analysis, substantially all of them correspond to an unsaturated disaccharide unit of chondroitin.
Owner:SEIKAGAKU KOGYO CO LTD
Low molecular weight carboxyl-reduced derivatives of fucosylated glycosaminoglycans and preparation method and applications of low molecular weight carboxyl-reduced derivatives
The invention discloses low molecular weight carboxyl-reduced derivatives of fucosylated glycosaminoglycans (LCRG). The extent of carboxyl reduction is not less than 20%. Weight-average molecular weight of the LCRG is about 3000-20000Da, and monosaccharides comprise acetyl galactosamine (GalNAc), glucose (Glc) or glucuronic acid (GlcUA) and fucose (Fuc) or sulfates of fucose (shown as -OSO3-). The mole ratio of GalNAc, Glc (containing GlcUA), Fuc and -OSO3- is about 1: (1+-0.3): (1+-0.3): (3.0+-1.0). The LCRG is a potent human immunodeficiency virus (HIV) Type 1 entry inhibitor which acts on conserved regions and has the advantages of high activity against HIV Type 1, high therapeutic index and no-drug-resistance, and the LCRG can be used for preventing or curing HIV. The invention further provides a preparation method of the LCRG. The carboxyl-reduced derivatives of fucosylated glycosaminoglycans and medicinal compositions of the carboxyl-reduced derivatives can be prepared into injection agents, lyophilized powder or suppository and the like.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI +1
Chondroitin synthetase and dna encoding the enzyme
A human-derived novel chondroitin synthase, which is an enzyme for synthesizing a fundamental backbone of chondroitin and has both glucuronic acid transferase activity and N-acetylgalactosamine transferase activity.
Owner:SEIKAGAKU KOGYO CO LTD +1
Method for preparing hemicellulose/nano-silver colloid rapidly
The invention discloses a method for preparing a hemicellulose / nano-silver colloid rapidly. The method includes the steps that in a water phase, hemicellulose and silver ammonia solution are subjected to a redox reaction under the microwave condition to generate nano-silver particles; the hemicellulose is extracted from the grass family, the weight-average molecular weight of the hemicellulose is 4.5*104 g / mol-5.5*104 g / mol, and the hemicellulose comprises, by mass percent, the following carbohydrate components: 85-90% of wood sugar, 7.5-12% of arabinose, 0.5-1% of glucose, 0.15-0.65% of galactose, 0.08-0.15% of mannose and 1.05-2.95% of glucuronic acid. The preparation meets the requirement for green chemistry, and the method is a nano-metal preparing method which is green and rapid to implement. A new conception is provided for the green synthesis of nano-silver, the hemicellulose resource is reasonably utilized, and the nano-silver colloid has application prospects in the biological field and the medical field.
Owner:SOUTH CHINA UNIV OF TECH
Ziyang selenium-rich green tea selenium-containing polysaccharide, and preparation method and application thereof
ActiveCN102417544AProtectiveHigh purityOrganic active ingredientsDigestive systemHeterosaccharideLactose
The invention discloses a Ziyang selenium-rich green tea selenium-containing polysaccharide, which comprises the following components in percentage by mass: 1.5-8.5 ppm selenium and the balance of heterosaccharide. The heterosaccharide comprises the following components in percentage by mol: 3.3-5.3% of mannitose, 1-2% of ribose, 3.5-5% of rhamnose, 2-3.5% of glucuronic acid, 2.6-3.8% of galacturonic acid, 30-34.2% of glucose, 3.6-5.6% of xylose, 19.8-23.2% of galactose and 21.5-25.6% of arabinose. The invention also provides a preparation method and application of the Ziyang selenium-rich green tea selenium-containing polysaccharide. The preparation method is simple and convenient, has the advantage of low cost, and is suitable for popularization; and the selenium-containing polysaccharide has the action of enhancing immunity, has obvious inhibiting actions on growth of colon cancer cells, and has obvious protective actions on hepatic injury.
Owner:SHAANXI NORMAL UNIV
Low molecular weight glycosylated chondroitin sulfate and its purpose in preparation of anti-HIV-1 medicament
InactiveCN102247401AAvoid drug resistanceDepolymerization speed is stableOrganic active ingredientsAntiviralsMonosaccharide compositionUltrafiltration
The invention discloses a low molecular weight glycosylated chondroitin sulfate, whose weight average molecular weight is 3000-15000Da. The monosaccharide composition comprises acetyl galactosamine (D-GalNAc), glucuronic acid (D-GlcUA), fucose (L-Fuc), or its sulfuric ester (expressed in -OS03<->), wherein the mole ratio of D-GalNAc to D-GlcUA to L-Fuc to -OS03<-> is 1: (1+ / -0.3): (1+ / -0.3): (3.5+ / -0.5). The low molecular weight glycosylated chondroitin sulfate has a strong anti-HIV-1 virus activity, is a gp120 entry inhibitor, and can be used for preventing and / or treating AIDS. The invention also provides a method for preparing the low molecular weight glycosylated chondroitin sulfate and its composition preparation. Glycosylated chondroitin sulfate is depolymerized by the peroxide method to obtain a low molecular weight product, and then low molecular and / or high-molecular impurities of the product are removed by gel separation or ultrafiltration method. The low molecular weight glycosylated chondroitin sulfate and its medicinal composition can be prepared in the form of an injection, a lyophilized powder or a suppository.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI +1
Method for synthesizing 5,6,4'-trihydroxyflavone-7-O-D-glucuronic acid
InactiveCN101538299AStrong space selectivityEasy to industrializeOrganic active ingredientsSugar derivativesChemical reactionCinnamoyl chloride
The invention provides a chemical method for preparing 5,6,4'-trihydroxyflavone-7-O-D-glucuronic acid to solve problems of unavailable raw materials, long synthetic route and low synthesis yield in the existing synthetic method. The method comprises a plurality of chemical reaction steps: first, taking 3,4,5-trimethoxy phenol and p-methoxy cinnamoyl chloride as the raw materials to construct a chalcone structure by a Friedel-Crafts acylation reaction, and cycloetherifying to obtain a flavone parent substance; then protecting and selectively deprotecting phenolic hydroxyl of the flavone parent substance, and glycosylating 7-phenolic hydroxyl; and finally removing a protective group to obtain the target compound. The obtained product has a beta-steric configuration. The method can be used for preparing high-purity and high-quality 5,6,4'-trihydroxyflavone-7-O-D-glucuronic acid products.
Owner:四川抗菌素工业研究所有限公司
Biodegradable Hyaluronic Acid Derivative, Biodegradable Polymeric Micelle Composition and Pharmaceutical or Bioactive Composition
The invention provides a biodegradable hyaluronic acid derivative including at least one modified hyaluronic acid repeating unit represented by the formula (HA)-[O(C═O)NH-M]p, wherein HA is a unit including N-acetyl-D-glucosamine and D-glucuronic acid, M is a modifying moiety containing a C2-16 hydrocarbyl group, and p is an integer of 1 to 4.
Owner:IND TECH RES INST
Cosmetic and Method for Production Thereof
ActiveUS20090280149A1Improve emulsion stabilityCosmetic preparationsSugar derivativesSide chainSilicic acid
A cosmetic in an emulsified state, in which a titanium dioxide microparticle coated with hydrous silicic acid and / or a hydrous silicate compound, a higher alcohol, an oily component other than the higher alcohol, and a polysaccharide are contained, and the polysaccharide containing at least one of fucose, glucose, glucuronic acid and rhamnose as a constituent monosaccharide, and having fucose and / or rhamnose in a side chain is contained in an amount of 0.01% by weight to 1% by weight relative to the total amount of the cosmetic. And a cosmetic containing the higher alcohol, the oily component and the polysaccharide in an emulsified state, in which the higher alcohol is composed of two or more kinds of higher alcohols having different molecular weights, and is contained in the cosmetic in an amount of 1% by weight to 20% by weight relative to the total amount of the cosmetic. The oily component is contained in an amount of 1% by weight to 20% by weight relative to the total amount of the cosmetic, and the polysaccharide is contained in an amount of 0.01% by weight to 1% by weight relative to the total amount of the cosmetic, and a producing method thereof.
Owner:HAKUTO CHEMICAL CO LTD +1
Low-molecular-weight fucosylated chondroitin sulfate, preparation method thereof and application of low-molecular-weight fucosylated chondroitin sulfate to preparation of medicine for resisting Trousseau syndrome
InactiveCN106349407ARich sourcesNo pollution in the processOrganic active ingredientsAntineoplastic agentsSulfated polysaccharidesOligosaccharide
The invention provides low-molecular-weight fucosylated chondroitin sulfate, a preparation method thereof and application of the low-molecular-weight fucosylated chondroitin sulfate to the preparation of medicine for resisting Trousseau syndrome. Sulfated polysaccharide with the main chain using beta-1,4-D-glucuronic acid and beta-1,3-D-acetamino galactose as disaccharide repeating units and the branch chain being alpha-1,3-L-fucus oligosaccharide sulfate. Experiments show that the fucosylated chondroitin sulfate has an evident inhibiting effect on the Trousseau syndrome. The fucosylated chondroitin sulfate is rich in raw material source, simple in preparation process, easy in industrialization, high in product safety, good in stability, unique in activity, promising in technical prospect in the development of medicine for resisting the Trousseau syndrome, and the like.
Owner:OCEAN UNIV OF CHINA
Biosynthesis method of glucuronic acid and glucuric acid
ActiveCN104312987AEfficient yieldEfficient productionBacteriaMicroorganism based processesPichia pastorisEscherichia coli
The invention discloses a biosynthesis method of glucuronic acid and glucuric acid, belonging to the field of metabolic engineering. The biosynthesis method is characterized by expressing myo inositol oxygenase (MIOX) from pichia pastoris in Escherichia coli to convert myo inositol into glucuronic acid, and expressing aldehyde acid dehydrogenase (Udh) from pseudomonas putida to convert produced glucuronic acid into glucuric acid, thereby successfully establishing a synthesis path from myo inositol to glucuric acid. Recombinant Escherichia coli established by the method has very great application prospect, and a new idea is provided for generating glucuronic acid and glucuric acid through conversion by the biological method.
Owner:江苏弘康未来营养科技有限公司
Method for content determination of multiple components in traditional Chinese medicinal preparation Shuanghuanglian for injection
ActiveCN103308615AAvoid driftingSolve the precipitation problemComponent separationIsochlorogenic acidContent determination
The invention relates to a method for content determination of multiple components in traditional Chinese medicinal preparation Shuanghuanglian for injection, aiming at solving the problems of an existing method for content determination of Shuanghuanglian for injection which is complex in sample processing, time, labor and detection equipment-consuming to detect Shuanghuanglian, and long in detection period. The detection method provided by the invention can be used for synchronously determining the contents of more than 10 components such as forsythin, forsythiaside A, caffeic acid, neochlorogenic acid, chlorogenic acid, cryptochlorogenin acid, isochlorogenic acid A, isochlorogenic acid C, baicalin, scutellarin and oroxylin-7-O-glucuronic acid in the Shuanghuanglian for injection, and meanwhile monitoring a fingerprint spectrum. The method can be used for completing previous detection in one time just by one detection system, and is more accurate, stable, comprehensive and rapid in control over the quality of the Shuanghuanglian for injection.
Owner:哈药集团中药有限公司
Method for testing quality of perfoliate knotweed medicinal materials
InactiveCN101549021AImprove quality inspection standardsHigh precisionSenses disorderAntipyreticMedicinal herbsTest quality
The invention discloses a method for testing quality of perfoliate knotweed medicinal material, which includes part or whole of description, identification, examination and content measurement. The aforementioned identification includes thin-layered chromatography of taking quercetin reference substance and / or quercetin-3-O-beta-D-n butyl glucuronic acid reference substance as contrast, the content measurement measures the content of quercetin in medicinal materials, which is indicated as a high performance liquid chromatography of taking quercetin as contrast and the organic facies : aqueous phase as 10-40 : 90-60. Compared to the existing technology, the invention perfects the quality detecting standard of perfoliate knotweed medicinal materials, recuperates the deficiency of the existing quality detecting technology, which makes this quality detecting technology more scientific and reasonable, and ensures its security and validity in clinical application.
Owner:GUIZHOU NORMAL UNIVERSITY
Conjugates comprising a central nervous system-active drug linked to glucuronic acid or glucosamine through an amide bond and uses thereof
Disclosed are conjugates comprising a central nervous system-active drug linked through an amide bond to a glucuronic acid or glucosamine moiety, and uses thereof, e.g., for treating or ameliorating central nervous system diseases or disorders.
Owner:HOLICK MICHAEL F +1
Polymer and use thereof
InactiveCN101372515AHigh viscosityGood thickening effectDrilling compositionFood preparationArginineValine
The invention belongs to the field of energy technology and food technology, and more particularly relates to a polymer and the application thereof. The polymer is composed of 34.8% of sugar, 63.1% of fat and 1.5% of polypeptide; wherein, the sugar component contains glucose, rhamnose, seminose and glucuronic acid; fat component contains 6.2% of hexadecanoic acid methyl ester and 93.8% of methyl stearate; the polypeptide component respectively contains 11.6% of asparticacid, 6.1% of threonine, 4.8% of serine, 11.7% of glutamic acid, 6.7% of glycin, 9.8% of lactamine, 6.7% of valine, 1.8% of methionine , 4.6% of isoleucine, 9.8% of leucine, 3.4% of tyrosine, 5.9% of phenyl alanine, 3.1% of lysine, 1.3% of histidine, 7.6% of arginine and 5.2% of proline. Sanzanjiao can be taken as drilling mud conditioner and jelly glue polymer used for water shutoff profile control treatment in oil field to be applied to petroleum extraction, and the characteristics of jelling and thickening lead the polymer to be taken as food additive to be widely applied to the food production field.
Owner:张禹
Spirulina polysaccharide and application thereof
ActiveCN105707072AInduced plant disease resistanceNatural sourceBiocideAlgae medical ingredientsMonosaccharide compositionFreeze-drying
The invention relates to glucose-rich spirulina polysaccharide and an application thereof in a plant green pesticide and an anti-tumor drug. High-sugar spirulina obtained through nutritional regulation is used as a raw material and is subjected to hot water extraction, protein removal with a flocculant, concentration, precipitation and freeze drying to obtain the water-soluble high-sugar spirulina polysaccharide having the molecular weight of 10-200 kDa; the spirulina polysaccharide comprises the monosaccharides mainly comprising rhamnose, fucose, arabinose, xylose, mannose, galactose, glucose, glucuronic acid and galacturonic acid, and is characterized in that the glucose content is more than 50% in the monosaccharide composition. The spirulina polysaccharide can obviously induce plant disease resistance, has obvious anti-tumor effect on tumor, and can be used as the biological pesticide and the anti-tumor drug.
Owner:DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Enzymatic synthesis of sulfated polysaccharides
Heparin is synthesized from a polysaccharide comprised of a 1-4 glycosidically linked alternating polymer of uronic acid and glucosamine residues, wherein the uronic acid is selected from iduronic and glucuronic acid, wherein the glucosamine is partially N-sulfated; by a series of selective reactions catalyzed by recombinant enzymes.
Owner:THE UNIV OF NORTH CAROLINA AT CHAPEL HILL +1
Chondroitin systhetase and nucleic acid coding for the enzyme
A human-derived novel chondroitin synthase, which is an enzyme for synthesizing a fundamental backbone of chondroitin and has both glucuronic acid transferring activity and N-acetylgalactosamine transferring activity.
Owner:SEIKAGAKU KOGYO CO LTD +1
Biodegradable hyaluronic acid derivative and biodegradable polymeric micelle composition
InactiveUS20050123505A1Powder deliveryPharmaceutical non-active ingredientsN Acetyl D GlucosaminePrepolymer
A biodegradable hyaluronic acid derivative comprising a modified hyaluronic acid repeating unit represented by the formula (HA)-[O(C═O)NH-M]p, wherein HA is a unit including N-acetyl-D-glucosamine and D-glucuronic acid, M is a modifying moiety containing a C2-16 hydrocarbyl group or a prepolymer, and p is an integer of 1 to 4. The biodegradable hyaluronic acid derivative when dissolved in a hydrophilic medium can form micelles and can be used to entrap a pharmaceutically active or bioactive molecule.
Owner:IND TECH RES INST
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com